Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, lacking targeted therapies due to its molecular characteristics. Tumor-associated ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

The application of ferroptosis inhibitors can alleviate the development of AD in both cellular and animal models. Herein, a series of dual-functional hydroxylated chalcone derivatives by ...

A key discovery was the activation of the HIF1α-HMOX1 axis, which drives excessive autophagy and ferritin degradation, leading to intracellular iron overload and lipid peroxidation, hallmarks of ...

Melanoma, one of the most aggressive forms of skin cancer, often metastasizes to bones, causing severe bone loss, an increased risk of fractures, and significant pain. Bone metastasis is associated ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

2014). Martin-Sanchez confirmed the presence of the characteristics of ferroptosis in folate-induced mouse AKI models, which are lipid peroxidation and downregulation of GSH (Martin-Sanchez et al., ...

I'm talking about the fact that Geron is evaluating the use of this drug in the phase 3 IMpactMF study to target JAK inhibitor [JAKi] relapsed/refractory Myelofibrosis [MF] patients. The study has ...